Literature DB >> 9724016

Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease.

T Müller1, D Blum-Degen, H Przuntek, W Kuhn.   

Abstract

INTRODUCTION: Several lines of evidence suggest that neuroimmune mechanisms may also be involved in neurodegeneration in Parkinson's disease (PD). The potential role of cytokines such as interleukin 6 (IL-6), in the interaction between neurons and immune system has been emphasized by recent findings. IL-6 induces acute phase protein synthesis, differentiation of neuronal cells and improves catecholaminergic and cholinergic cell survival in the brain. SUBJECTS AND METHODS: We determined levels of IL-6 in cerebrospinal fluid (CSF) of untreated parkinsonian patients and age- and sex-matched controls. Intensity of disease was evaluated by the Unified Parkinson's Disease Rating scale.
RESULTS: Significantly elevated levels of IL-6 were found in the CSF of parkinsonian patients. Moreover a significant inverse correlation between severity of PD and IL-6 CSF levels appeared. DISCUSSION: Elevated IL-6 levels in the CSF of untreated parkinsonian patients may reflect the original condition in the course of disease. We speculate that an endogenous upregulation of IL-6 synthesis occurs in order to regenerate lesioned neurons probably at an early phase of the degenerative process in PD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724016     DOI: 10.1111/j.1600-0404.1998.tb01736.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  58 in total

1.  Interleukin-6 trans-signaling in the senescent mouse brain is involved in infection-related deficits in contextual fear conditioning.

Authors:  Michael D Burton; Rodney W Johnson
Journal:  Brain Behav Immun       Date:  2011-10-29       Impact factor: 7.217

Review 2.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

3.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

4.  Interleukin-6 serum levels in patients with Parkinson's disease.

Authors:  Kerly Wollmeister Hofmann; Artur Francisco Schumacher Schuh; Jonas Saute; Raquel Townsend; Daniele Fricke; Renata Leke; Diogo O Souza; Luis Valmor Portela; Márcia Lorena Fagundes Chaves; Carlos R M Rieder
Journal:  Neurochem Res       Date:  2009-02-13       Impact factor: 3.996

5.  Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.

Authors:  Alexandra Isabel Rosa; Sara Duarte-Silva; Anabela Silva-Fernandes; Maria João Nunes; Andreia Neves Carvalho; Elsa Rodrigues; Maria João Gama; Cecília Maria Pereira Rodrigues; Patrícia Maciel; Margarida Castro-Caldas
Journal:  Mol Neurobiol       Date:  2018-04-12       Impact factor: 5.590

Review 6.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

Review 7.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 8.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

9.  Interleukin 6 and complement serum level study in Parkinson's disease.

Authors:  Branislav Veselý; Michal Dufek; Vojtech Thon; Miroslav Brozman; Silvia Királová; Tatiana Halászová; Eva Koriťáková; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2018-02-12       Impact factor: 3.575

Review 10.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.